Healthcare Professionals

• Why KOGENATE^® Bayer?

• Terumo^® Safety Butterfly

• Prophylaxis

• FAQs
• Request medical information

Bayer Links

• Bayer UK/I
• Factor Fitness

• General Conditions of Use
• Privacy Statement
• Imprint

Efficacy

Patient information

You can download the following files in PDF format :

The clinical evolution of KOGENATE^® Bayer and its predecessor Kogenate^® includes 20 years of clinical and market experience and multicentre international studies.

The pharmacokinetics, safety, and efficacy of Kogenate^®, were investigated in more than 200 patients with haemophilia A.¹ The results of these international multicentre clinical trials demonstrated that Kogenate^® has biological activity comparable with that of pdFVIII and it was efficacious with an appropriate safety profile for the treatment of haemophilia A.

KOGENATE^® Bayer was evaluated in multicentre clinical trials including 71 previously treated patients (PTPs) (Abshire et al, 2000) and 61 previously untreated patients (PUPs) or minimally treated patients (MTPs) (Kreuz et al, 2005).

Well-documented haemostasis

Click the following links for clinical data:

Bleed control in PTPsBleed control in PUPs

References

1. Schwartz et al, 1990; Aygören-Pürsün and Scharrer 1997; Seremetis et al, 1999; Lusher et al, 2004

Produced by Bayer. This website is intended for HealthCare professionals.
Date of preparation: December 2010 UK.PH.HN.KOG.2010.250.14.3